Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment
Identifieur interne : 000127 ( Main/Corpus ); précédent : 000126; suivant : 000128Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment
Auteurs : Jaime Kulisevsky ; Javier PagonabarragaSource :
- Movement Disorders [ 0885-3185 ] ; 2009-06-15.
English descriptors
- KwdEn :
Abstract
Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini‐Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD‐specific scales (Mini‐Mental Parkinson, Scales for Outcomes of Parkinson's disease—Cognition, Parkinson's Disease—Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA‐COG and the PD‐CRS have undergone extensive and rigorous validation processes. While the SCOPA‐COG mainly assesses “frontal‐subcortical” cognitive defects, the PD‐CRS also assesses “instrumental‐cortical” functions, allowing better characterization of the different patterns of CI that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for CI and have not yet been subjected to extensive clinimetric evaluations. Further research on PD‐specific tools seems mandatory to help establish accurate cut‐off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22506
Links to Exploration step
ISTEX:A3E4D04CF7713514A002AE15A695EE03BF077772Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Pagonabarraga, Javier" sort="Pagonabarraga, Javier" uniqKey="Pagonabarraga J" first="Javier" last="Pagonabarraga">Javier Pagonabarraga</name><affiliation><mods:affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A3E4D04CF7713514A002AE15A695EE03BF077772</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22506</idno><idno type="url">https://api.istex.fr/document/A3E4D04CF7713514A002AE15A695EE03BF077772/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Pagonabarraga, Javier" sort="Pagonabarraga, Javier" uniqKey="Pagonabarraga J" first="Javier" last="Pagonabarraga">Javier Pagonabarraga</name><affiliation><mods:affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06-15">2009-06-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1103">1103</biblScope><biblScope unit="page" to="1110">1110</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A3E4D04CF7713514A002AE15A695EE03BF077772</idno><idno type="DOI">10.1002/mds.22506</idno><idno type="ArticleID">MDS22506</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cognition</term><term>dementia</term><term>neuropsychological</term><term>scale</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini‐Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD‐specific scales (Mini‐Mental Parkinson, Scales for Outcomes of Parkinson's disease—Cognition, Parkinson's Disease—Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA‐COG and the PD‐CRS have undergone extensive and rigorous validation processes. While the SCOPA‐COG mainly assesses “frontal‐subcortical” cognitive defects, the PD‐CRS also assesses “instrumental‐cortical” functions, allowing better characterization of the different patterns of CI that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for CI and have not yet been subjected to extensive clinimetric evaluations. Further research on PD‐specific tools seems mandatory to help establish accurate cut‐off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jaime Kulisevsky MD, PhD</name><affiliations><json:string>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Javier Pagonabarraga MD</name><affiliations><json:string>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognition</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuropsychological</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>scale</value></json:item></subject><articleId><json:string>MDS22506</json:string></articleId><language><json:string>eng</json:string></language><abstract>Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini‐Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD‐specific scales (Mini‐Mental Parkinson, Scales for Outcomes of Parkinson's disease—Cognition, Parkinson's Disease—Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA‐COG and the PD‐CRS have undergone extensive and rigorous validation processes. While the SCOPA‐COG mainly assesses “frontal‐subcortical” cognitive defects, the PD‐CRS also assesses “instrumental‐cortical” functions, allowing better characterization of the different patterns of CI that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for CI and have not yet been subjected to extensive clinimetric evaluations. Further research on PD‐specific tools seems mandatory to help establish accurate cut‐off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>7.877</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1801</abstractCharCount><pdfWordCount>4937</pdfWordCount><pdfCharCount>33610</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>245</abstractWordCount></qualityIndicators><title>Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title><genre><json:string>review-article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>1110</last><first>1103</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22506</json:string></doi><id>A3E4D04CF7713514A002AE15A695EE03BF077772</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A3E4D04CF7713514A002AE15A695EE03BF077772/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A3E4D04CF7713514A002AE15A695EE03BF077772/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A3E4D04CF7713514A002AE15A695EE03BF077772/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="content">*This article is part of the journal's online CME program. The CME activity including form, can be found on line at http://www.movementdisorders.org/education/journalcme/</note><note>Merck Serono International S.A.</note><note>Merck KGaA, Darmstadt, Germany</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title><author><persName><forename type="first">Jaime</forename><surname>Kulisevsky</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, Sant Antoni M. Claret 167, 08025 Barcelona, Spain</p></note><affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Javier</forename><surname>Pagonabarraga</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1103">1103</biblScope><biblScope unit="page" to="1110">1110</biblScope></imprint></monogr><idno type="istex">A3E4D04CF7713514A002AE15A695EE03BF077772</idno><idno type="DOI">10.1002/mds.22506</idno><idno type="ArticleID">MDS22506</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini‐Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD‐specific scales (Mini‐Mental Parkinson, Scales for Outcomes of Parkinson's disease—Cognition, Parkinson's Disease—Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA‐COG and the PD‐CRS have undergone extensive and rigorous validation processes. While the SCOPA‐COG mainly assesses “frontal‐subcortical” cognitive defects, the PD‐CRS also assesses “instrumental‐cortical” functions, allowing better characterization of the different patterns of CI that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for CI and have not yet been subjected to extensive clinimetric evaluations. Further research on PD‐specific tools seems mandatory to help establish accurate cut‐off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>cognition</term></item><item><term>dementia</term></item><item><term>neuropsychological</term></item><item><term>scale</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-20">Received</change><change when="2009-01-26">Registration</change><change when="2009-06-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A3E4D04CF7713514A002AE15A695EE03BF077772/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v24:8</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2009-06-15">15 June 2009</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="1" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22506</doi><idGroup><id type="unit" value="MDS22506"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-20"></event><event type="manuscriptAccepted" date="2009-01-26"></event><event type="firstOnline" date="2009-04-07"></event><event type="publishedOnlineFinalForm" date="2009-06-18"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-04-07"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1103</numbering><numbering type="pageLast">1110</numbering></numberingGroup><correspondenceTo>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, Sant Antoni M. Claret 167, 08025 Barcelona, Spain</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22506.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="53"></count><count type="wordTotal" number="5448"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment<link href="#fn1"></link> <link href="#fn3"></link></title><title type="short" xml:lang="en">Cognitive Tools in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jaime</givenNames><familyName>Kulisevsky</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>jkulisevsky@santpau.cat</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Javier</givenNames><familyName>Pagonabarraga</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">cognition</keyword><keyword xml:id="kwd3">dementia</keyword><keyword xml:id="kwd4">neuropsychological</keyword><keyword xml:id="kwd5">scale</keyword></keywordGroup><fundingInfo><fundingAgency>Merck Serono International S.A.</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Merck KGaA, Darmstadt, Germany</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini‐Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD‐specific scales (Mini‐Mental Parkinson, Scales for Outcomes of Parkinson's disease—Cognition, Parkinson's Disease—Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA‐COG and the PD‐CRS have undergone extensive and rigorous validation processes. While the SCOPA‐COG mainly assesses “frontal‐subcortical” cognitive defects, the PD‐CRS also assesses “instrumental‐cortical” functions, allowing better characterization of the different patterns of CI that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for CI and have not yet been subjected to extensive clinimetric evaluations. Further research on PD‐specific tools seems mandatory to help establish accurate cut‐off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note><note xml:id="fn3"><p>This article is part of the journal's online CME program. The CME activity including form, can be found on line at <url href="http://www.movementdisorders.org/education/journalcme/">http://www.movementdisorders.org/education/journalcme/</url></p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cognitive Tools in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment</title></titleInfo><name type="personal"><namePart type="given">Jaime</namePart><namePart type="family">Kulisevsky</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</affiliation><description>Correspondence: Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, Sant Antoni M. Claret 167, 08025 Barcelona, Spain</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Javier</namePart><namePart type="family">Pagonabarraga</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Autonomous University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-06-15</dateIssued><dateCaptured encoding="w3cdtf">2008-10-20</dateCaptured><dateValid encoding="w3cdtf">2009-01-26</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">53</extent><extent unit="words">5448</extent></physicalDescription><abstract lang="en">Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini‐Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD‐specific scales (Mini‐Mental Parkinson, Scales for Outcomes of Parkinson's disease—Cognition, Parkinson's Disease—Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA‐COG and the PD‐CRS have undergone extensive and rigorous validation processes. While the SCOPA‐COG mainly assesses “frontal‐subcortical” cognitive defects, the PD‐CRS also assesses “instrumental‐cortical” functions, allowing better characterization of the different patterns of CI that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for CI and have not yet been subjected to extensive clinimetric evaluations. Further research on PD‐specific tools seems mandatory to help establish accurate cut‐off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="content">*This article is part of the journal's online CME program. The CME activity including form, can be found on line at http://www.movementdisorders.org/education/journalcme/</note><note type="funding">Merck Serono International S.A.</note><note type="funding">Merck KGaA, Darmstadt, Germany</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>cognition</topic><topic>dementia</topic><topic>neuropsychological</topic><topic>scale</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1103</start><end>1110</end><total>8</total></extent></part></relatedItem><identifier type="istex">A3E4D04CF7713514A002AE15A695EE03BF077772</identifier><identifier type="DOI">10.1002/mds.22506</identifier><identifier type="ArticleID">MDS22506</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:A3E4D04CF7713514A002AE15A695EE03BF077772
|texte= Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment
}}
| This area was generated with Dilib version V0.6.23. |  |